Kyverna Therapeutics
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Total operating expenses were $62,406,000.
Profit Margin
| 2023 | 0 | -60.36M |
|---|
KYTX Income Statement (2023 – 2023)
| 2023 | |
|---|---|
Revenue | |
Revenue | 0 |
Cost of revenue | 1.70M |
Gross profit | -1.70M |
Operating exp. | |
Research and development | 49.92M |
Selling and marketing | 0 |
Total operating expenses | 62.40M |
Operating income | -62.40M |
Other income (expenses), net | 2.04M |
Income before tax | -60.36M |
Income tax expense | 0 |
Net income | -60.36M |
Earnings per share | |
Basic EPS | -0.00 |
Diluted EPS | -0.00 |
| Data source |